Literature DB >> 33666070

Bronchoscopy in COVID-19 patients: When, how and why. Experience in clinical practice.

Carmine Guarino1, Cristiano Cesaro2, Giuseppe Fiorentino3, Francesco Rossi4, Benedetto Maria Polverino5, Fiorentino Fragranza6, Luca Monastra7, Patrizia Murino8, Enzo Zamparelli9, Giuseppe La Cerra10.   

Abstract

Severe Acute Respiratory Syndrome due to Coronavirus-19 (SARS-CoV-2) is caused by combined alveolar-capillary lung damage, with bilateral pneumonia and thrombosis, which often causes respiratory failure. Proper COVID-19 management requires high skills in airway control and the need to perform aerosol-generating procedures such as bronchoscopy, which can increase the possibility of virus spreading among healthcare professionals. In an epidemiologically delicate moment, the multidisciplinary decision on "WHEN, HOW and WHY" to perform bronchoscopies minimizing the risk of COVID-19 transmission, represented a great challenge for all specialists engaged in bronchoscopic procedures. In this work authors want to share all technical aspects of 87 videobronchoscopies performed in confirmed or suspected COVID-19 patients, from 3rd to 6th January 2020, describing the reason, the organizational and operational model and patients characteristics. Was also evaluated the impact of high-risk procedures such as bronchoscopy on the personnel involved. The disclosure of all technical details, represents, in the opinion of the authors, an important contribution, capable of providing support to all physicians engaged in bronchoscopy procedures in confirmed or suspected COVID-19 patients.

Entities:  

Mesh:

Year:  2021        PMID: 33666070     DOI: 10.4081/monaldi.2021.1744

Source DB:  PubMed          Journal:  Monaldi Arch Chest Dis        ISSN: 1122-0643


  1 in total

Review 1.  Severe Thrombocytopenia as a Manifestation of COVID-19 Infection.

Authors:  Mihaela Mocan; Roxana Mihaela Chiorescu; Andrada Tirnovan; Botond Sandor Buksa; Anca Daniela Farcaș
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.